Department of Hospital Medicine, Cleveland Clinic, Cleveland, OH 44195, United States.
Department of Internal Medicine, Cleveland Clinic, Cleveland, OH 44195, United States.
World J Gastroenterol. 2021 Jun 28;27(24):3682-3692. doi: 10.3748/wjg.v27.i24.3682.
With increasing rates of liver transplantation and a stagnant donor pool, the annual wait list removals have remained high. Living donor liver transplantation (LDLT) is an established modality in expanding the donor pool and is the primary method of liver donation in large parts of the world. Marginal living donors, including those with hepatic steatosis, have been used to expand the donor pool. However, due to negative effects of steatosis on graft and recipient outcomes, current practice excludes overweight or obese donors with more than 10% macro vesicular steatosis. This has limited a potentially important source to help expand the donor pool. Weight loss is known to improve or resolve steatosis and rapid weight loss with short-term interventions have been used to convert marginal donors to low-risk donors in a small series of studies. There is, however, a lack of a consensus driven standardized approach to such interventions.
To assess the available data on using weight loss interventions in potential living liver donors with steatotic livers and investigated the feasibility, efficacy, and safety of using such donors on the donor, graft and recipient outcomes. The principal objective was to assess if using such treated donor livers, could help expand the donor pool.
We performed a comprehensive literature review and meta-analysis on studies examining the role of short-term weight loss interventions in potential living liver donors with hepatic steatosis with the aim of increasing liver donation rates and improving donor, graft, and recipient outcomes.
A total of 6 studies with 102 potential donors were included. Most subjects were males (71). All studies showed a significant reduction in body mass index post-intervention with a mean difference of -2.08 (-3.06, 1.10, = 78%). A significant reduction or resolution of hepatic steatosis was seen in 93 of the 102 (91.2%). Comparison of pre- and post-intervention liver biopsies showed a significant reduction in steatosis with a mean difference of -21.22 (-27.02, -15.43, = 56%). The liver donation rates post-intervention was 88.5 (74.5, 95.3, = 42%). All donors who did not undergo LDLT had either recipient reasons or had fibrosis/steatohepatitis on post intervention biopsies. Post-operative biliary complications in the intervention group were not significantly different compared to controls with an odds ratio of 0.96 [(0.14, 6.69), = 0]. The overall post-operative donor, graft, and recipient outcomes in treated donors were not significantly different compared to donors with no steatosis.
Use of appropriate short term weight loss interventions in living liver donors is an effective tool in turning marginal donors to low-risk donors and therefore in expanding the donor pool. It is feasible and safe, with comparable donor, graft, and recipient outcomes, to non-obese donors. Larger future prospective studies are needed.
随着肝移植率的不断提高和供体池的停滞不前,每年的等待名单剔除率仍然很高。活体肝移植(LDLT)是扩大供体池的一种既定模式,也是世界上许多地区肝脏捐献的主要方式。边缘供体,包括有肝脂肪变性的供体,已被用于扩大供体池。然而,由于脂肪变性对移植物和受者预后的负面影响,目前的实践将体脂超过 10%的大泡性脂肪变性的超重或肥胖供体排除在外。这限制了一个潜在的重要来源,以帮助扩大供体池。减肥已知可以改善或解决脂肪变性,并且在一些小型研究中,短期干预的快速减肥已被用于将边缘供体转变为低风险供体。然而,对于此类干预措施,缺乏共识驱动的标准化方法。
评估在有脂肪变性肝脏的潜在活体肝供体中使用减肥干预措施的现有数据,并研究在供体、移植物和受者结局方面使用此类供体的可行性、有效性和安全性。主要目的是评估使用这些经治疗的供体肝脏是否有助于扩大供体池。
我们对检查短期减肥干预措施在有肝脂肪变性的潜在活体肝供体中的作用的研究进行了全面的文献复习和荟萃分析,目的是提高肝脏捐献率,并改善供体、移植物和受者结局。
共有 6 项纳入 102 名潜在供体的研究。大多数受试者为男性(71 名)。所有研究均显示干预后体重指数显著降低,平均差异为-2.08(-3.06,1.10,=78%)。102 名供体中的 93 名(91.2%)的肝脂肪变性得到显著减少或缓解。对干预前后的肝活检进行比较,发现脂肪变性显著减少,平均差异为-21.22(-27.02,-15.43,=56%)。干预后的肝移植率为 88.5%(74.5%,95.3%,=42%)。所有未行 LDLT 的供体要么因受者原因,要么因干预后活检显示纤维化/脂肪性肝炎而无法行 LDLT。干预组与对照组术后胆道并发症的比值比为 0.96((0.14,6.69),=0)。与无脂肪变性的供体相比,治疗后供体、移植物和受者的总体术后结局无显著差异。
在活体肝供体中使用适当的短期减肥干预措施是将边缘供体转变为低风险供体的有效工具,从而扩大供体池。它是可行和安全的,与非肥胖供体相比,具有可比的供体、移植物和受者结局。需要更大的前瞻性未来研究。